Immupharma PLC Last patient completes dosing in LupuzorT Trial (0003A)
December 21 2017 - 02:00AM
UK Regulatory
TIDMIMM
RNS Number : 0003A
Immupharma PLC
21 December 2017
21 DECEMBER 2017
ImmuPharma PLC
("ImmuPharma" or the "Company")
Last patient completes dosing in Lupuzor(TM) Pivotal Phase III
Study
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and
development company, is pleased to confirm that the last patient
has completed dosing within the 52-week, randomised,
double-blinded, Phase III clinical trial of Lupuzor(TM), its lead
programme for the potential breakthrough compound for Lupus, the
life threatening auto-immune disease.
Study summary as at 21 December 2017
-- 200 patients successfully recruited and randomised (dosed)
-- Last patient successfully completed dosing
-- Continued robust safety record which remains consistent with
Lupuzor(TM)'s product profile as shown in its previous Phase IIb
study
-- Top line results remain on track to be reported in Q1 2018
Commenting on the trial update, Tim McCarthy, Chairman of
ImmuPharma said: "We are delighted to announce this significant
milestone that all patients have now completed dosing in this
pivotal Phase III trial for Lupuzor(TM). Importantly we continue to
see robust safety and we look forward with continued confidence to
reporting top line results of the study in Q1 2018."
For more information on the trial please visit:
https://clinicaltrials.gov/ct2/show/NCT02504645
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014.
For further information please contact:
+ 44 (0) 20 7152
ImmuPharma plc (www.immupharma.org) 4080
Tim McCarthy, Chairman
Lisa Baderoon, Head of Investor Relations
Twitter: @immupharma + 44 (0) 7721 413496
Northland Capital Partners Limited (Joint
Broker)
Patrick Claridge, David Hignell, Jamie Spotswood,
Corporate Finance +44 (0)20 3861
Rob Rees, Corporate Broking 6625
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESUROWRBRAUUAA
(END) Dow Jones Newswires
December 21, 2017 02:00 ET (07:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Feb 2024 to Mar 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Mar 2023 to Mar 2024